Utilisation du midazolam dans l’état de mal épileptique réfractaire de l’enfant

Lampin, Marie Emilie; Dorkenoo, A; Lamblin, Marie‐Dominique; Botte, A.; Leclerc, F.; Auvin, Stéphane

doi:10.1016/j.neurol.2009.12.009

Cited by 6 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings are in accordance with previous literature, which highlight SE duration as a predictor of poor outcomes (31,32,35). We also identified that in our SRSE cohort, side effects from CI administration, such as respiratory failure and hypotension, were lower than expected based on prior reports (36)(37)(38). These findings may be related to ICD code underreporting once patients are intubated or receiving vasopressor agents, which may hinder our understanding of common complications in SRSE and warrants attention in clinical practice and future research studies.…”

Section: Sample Characteristicssupporting

confidence: 93%

Super-Refractory Status Epilepticus in Children: A Retrospective Cohort Study

Vasquez

Farias‐Moeller

Sánchez-Fernández

et al. 2021

Pediatric Critical Care Medicine

View full text Add to dashboard Cite

show abstract

Section: Sample Characteristicssupporting

confidence: 93%

Super-Refractory Status Epilepticus in Children: A Retrospective Cohort Study

Vasquez

Farias‐Moeller

Sánchez-Fernández

et al. 2021

Pediatric Critical Care Medicine

View full text Add to dashboard Cite

show abstract

“…[2][3][4] Our results are comparable to those reported in the literature assessing the use of midazolam for seizure control in the emergency setting and reporting success rates of 56 to 96.7%. 3,5,8,10,11,[13][14][15][16][17] To our knowledge, there are no studies comparing IV midazolam to either lorazepam or diazepam IV in the ED setting. Silbergleit and colleagues published a double-blind, randomized, noninferiority trial comparing the efficacy of IM midazolam to that of IV lorazepam: IM midazolam was at least as safe and effective as IV lorazepam.…”

Section: Discussionmentioning

confidence: 99%

“…12 Multiple studies have proven that midazolam is at least as effective as diazepam in terms of safety and risk of recurrence, with the advantage of providing a faster initiation of treatment, leading to more rapid seizure cessation. 3,5,8,10,11,[13][14][15][16][17][18][19] Midazolam has emerged as a highly efficacious drug in the treatment of impending SE, with several routes of administration exhibiting high bioavailability. 19 In a recent article proposing evidence-based and expert consensus practice guidelines, the Neurocritical Care Society lists midazolam as Class I, Level A for the emergent treatment of SE, as Class IIB, Level B for urgent treatment (continuous infusion), and as Class IIa, Level B for refractory treatment using the evidence rating system of the American Heart Association. )…”

mentioning

confidence: 99%

Quality assurance evaluation of a simple linear protocol for the treatment of impending status epilepticus in a pediatric emergency department 2 years postimplementation

Tourigny-Ruel

Diksic

Mok

et al. 2014

CJEM

View full text Add to dashboard Cite

Objective: To evaluate the efficacy and safety of a simple linear midazolam-based protocol for the management of impending status epilepticus in children up to 18 years of age. Methods: This is a descriptive, quality assessment, retrospective chart review of children presenting with the chief complaint of seizure disorder in the emergency department (ED) of a tertiary care pediatric hospital and a triage category of resuscitation or urgent from April 1, 2009, to August 31, 2011 In children with at least one seizure episode in the ED treated according to the linear protocol, three main outcomes were assessed: compliance, effectiveness, and complications. Results: Of the 128 children meeting the above study criteria, 68 had at least one seizure episode in the ED, and treatment was required to terminate at least one seizure episode in 46 of 68 patients (67.6%). Fifty-five seizure episodes were treated in the 46 patients: 51 of 55 seizure episodes were treated with midazolam (92.7%) and 4 of 55 with lorazepam or diazepam (7.3%). Of those treated with midazolam, 86.3% (44 of 51) were successfully treated with one or two doses of midazolam. The median seizure duration for all treated patients was 6 minutes. Of the 42 patients treated with midazolam, 7 required either continuous positive airway pressure or intubation, and two patients were treated for hypotension. One patient died of pneumococcal meningitis. Conclusion: This simple linear protocol is an effective and safe regimen for the treatment of impending status epilepticus in children. RÉ SUMÉObjectif: L'é tude visait à é valuer l'efficacité et l'innocuité d'un simple protocole liné aire, fondé sur le midazolam, pour le traitement d'un é tat de mal é pileptique imminent, chez des enfants â gé s de 18 ans et moins.

show abstract

Treatment of Refractory Status Epilepticus in Childhood

Schreiber

Gaillard

2010

Curr Neurol Neurosci Rep

View full text Add to dashboard Cite

Refractory status epilepticus (RSE) is characterized by a prolonged seizure that persists despite adequate initial management. RSE accounts for almost one quarter of all status epilepticus and carries significant risk for morbidity and mortality. Treatment varies widely between institutions regarding medication choice, dose, and monitoring. Several agents including nonanesthetic antiepileptic drugs (AEDs), anesthetic AEDs, enteral AEDs, and other therapies have been used in RSE. We review the current treatment strategies for RSE, focusing on patient selection, monitoring, optimal dosing and administration of medications, efficacy, adverse effects, and treatment duration.

show abstract

Utilisation du midazolam dans l’état de mal épileptique réfractaire de l’enfant

Cited by 6 publications

References 9 publications

Super-Refractory Status Epilepticus in Children: A Retrospective Cohort Study

Super-Refractory Status Epilepticus in Children: A Retrospective Cohort Study

Quality assurance evaluation of a simple linear protocol for the treatment of impending status epilepticus in a pediatric emergency department 2 years postimplementation

Treatment of Refractory Status Epilepticus in Childhood

Contact Info

Product

Resources

About